ATI RN
ATI Pathophysiology Final Exam
1. Cellular swelling is:
- A. Irreversible
- B. Evident early in all types of cellular injury
- C. Manifested by decreased intracellular sodium
- D. None of the above is correct
Correct answer: B
Rationale: Cellular swelling is indeed evident early in all types of cellular injury. This occurs due to the influx of water into the cell, leading to swelling. Choice A is incorrect because cellular swelling is reversible if the injury is not severe. Choice C is incorrect because cellular swelling is not manifested by decreased intracellular sodium; in fact, it is associated with increased intracellular sodium due to water influx. Choice D is incorrect as option B is the correct statement.
2. Which of the following correctly identifies the plasma protein inflammatory mediator systems?
- A. Phagocytic, interferon, and complement systems.
- B. Complement, fibrinolytic, and clotting systems.
- C. Complement, clotting, and kinin systems.
- D. Complement, clotting, and acute phase reactant systems.
Correct answer: C
Rationale: The correct answer is C: Complement, clotting, and kinin systems. These are the three main plasma protein inflammatory mediator systems. The complement system helps in inflammation and immune responses, the clotting system is involved in blood coagulation, and the kinin system regulates inflammation and blood pressure. Choice A is incorrect because interferon is not part of the plasma protein inflammatory mediator systems. Choice B is incorrect because the fibrinolytic system is not a primary inflammatory mediator system. Choice D is incorrect because acute phase reactants are not part of the plasma protein inflammatory mediator systems.
3. A patient is prescribed raloxifene (Evista) for osteoporosis. What is the primary mechanism of action for this medication?
- A. Raloxifene decreases bone resorption, which helps to maintain or increase bone density.
- B. Raloxifene increases calcium absorption in the intestines, which helps build stronger bones.
- C. Raloxifene stimulates new bone formation by increasing osteoblast activity.
- D. Raloxifene decreases calcium excretion by the kidneys, helping to maintain bone density.
Correct answer: A
Rationale: Raloxifene decreases bone resorption, which helps to maintain or increase bone density, making it effective in the prevention and treatment of osteoporosis.
4. Identify which conditions are due to excessive immune response.
- A. Allergies and onychomycosis
- B. Type II diabetes and smallpox
- C. Chronic renal failure and macular degeneration
- D. Allergies and rheumatoid arthritis
Correct answer: D
Rationale: The correct answer is D: Allergies and rheumatoid arthritis. Allergies are caused by an excessive immune response to harmless substances, while rheumatoid arthritis is an autoimmune disorder where the immune system attacks the body's tissues, leading to inflammation and joint damage. Choices A, B, and C are incorrect. Onychomycosis is a fungal infection of the nails, Type II diabetes is a metabolic disorder not primarily related to immune response, smallpox is a viral infection, chronic renal failure is a kidney condition, and macular degeneration is an eye disorder, none of which are directly linked to excessive immune response.
5. Which of the following is a cause of edema?
- A. Decreased plasma proteins
- B. Hypotension
- C. Dehydration
- D. Polyuria
Correct answer: A
Rationale: The correct answer is A: Decreased plasma proteins. Edema can be caused by decreased plasma proteins, which reduce the osmotic pressure that keeps fluid in the blood vessels. Hypotension (choice B) is low blood pressure and is not a direct cause of edema. Dehydration (choice C) involves a lack of body fluid, but it is not a direct cause of edema. Polyuria (choice D) is excessive urination and not a direct cause of edema.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access